Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naphak Modhiran

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
NPJ Vaccines|July 31, 2024
A chimeric vaccine derived from Australian genotype IV Japanese encephalitis virus protects mice from lethal challengeJessica J Harrison, Wilson Nguyen, Mahali S Morgan, et al.
Journal of Medicinal Chemistry|July 12, 2024
Amphiphilic Heparinoids as Potent Antiviral Agents against SARS-CoV-2Mohit Chhabra, Chethan D Shanthamurthy, Nanjudaswamy Vijendra Kumar, et al.
Frontiers in Immunology|June 27, 2022
Nucleocapsid Specific Diagnostics for the Detection of Divergent SARS-CoV-2 VariantsAriel Isaacs, Alberto A Amarilla, Julio Aguado, et al.
Vaccines|April 23, 2022
Dermal Delivery of a SARS-CoV-2 Subunit Vaccine Induces Immunogenicity against Variants of ConcernChristopher L D McMillan, Armira Azuar, Jovin J Y Choo, et al.
Frontiers in Immunology|September 5, 2022
A platform technology for generating subunit vaccines against diverse viral pathogensAndrew Young, Ariel Isaacs, Connor A P Scott, et al.
Science Advances|October 29, 2021
Complete protection by a single-dose skin patch-delivered SARS-CoV-2 spike vaccineChristopher L D McMillan, Jovin J Y Choo, Adi Idris, et al.
Viruses|January 21, 2023
Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of ConcernMahali S Morgan, Kexin Yan, Thuy T Le, et al.
Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Nature Microbiology|March 20, 2019
Determinants of Zika virus host tropism uncovered by deep mutational scanningYin Xiang Setoh, Alberto A Amarilla, Nias Y G Peng, et al.
Science (New York, N.Y.)|January 8, 2021
A broadly protective antibody that targets the flavivirus NS1 proteinNaphak Modhiran, Hao Song, Lidong Liu, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
NPJ Vaccines|July 31, 2024
A chimeric vaccine derived from Australian genotype IV Japanese encephalitis virus protects mice from lethal challengeJessica J Harrison, Wilson Nguyen, Mahali S Morgan, et al.
Journal of Medicinal Chemistry|July 12, 2024
Amphiphilic Heparinoids as Potent Antiviral Agents against SARS-CoV-2Mohit Chhabra, Chethan D Shanthamurthy, Nanjudaswamy Vijendra Kumar, et al.
Frontiers in Immunology|June 27, 2022
Nucleocapsid Specific Diagnostics for the Detection of Divergent SARS-CoV-2 VariantsAriel Isaacs, Alberto A Amarilla, Julio Aguado, et al.
Vaccines|April 23, 2022
Dermal Delivery of a SARS-CoV-2 Subunit Vaccine Induces Immunogenicity against Variants of ConcernChristopher L D McMillan, Armira Azuar, Jovin J Y Choo, et al.
Frontiers in Immunology|September 5, 2022
A platform technology for generating subunit vaccines against diverse viral pathogensAndrew Young, Ariel Isaacs, Connor A P Scott, et al.
Science Advances|October 29, 2021
Complete protection by a single-dose skin patch-delivered SARS-CoV-2 spike vaccineChristopher L D McMillan, Jovin J Y Choo, Adi Idris, et al.
Viruses|January 21, 2023
Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of ConcernMahali S Morgan, Kexin Yan, Thuy T Le, et al.
Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Nature Microbiology|March 20, 2019
Determinants of Zika virus host tropism uncovered by deep mutational scanningYin Xiang Setoh, Alberto A Amarilla, Nias Y G Peng, et al.
Science (New York, N.Y.)|January 8, 2021
A broadly protective antibody that targets the flavivirus NS1 proteinNaphak Modhiran, Hao Song, Lidong Liu, et al.
Pageof 8